Providence Capital Advisors’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.14M | Sell |
26,099
-1,022
| -4% | -$118K | 0.51% | 72 |
|
|
2025
Q4 | $2.85M | Sell |
27,121
-84,000
| -76% | -$7.89M | 0.48% | 73 |
|
|
2025
Q3 | $9.33M | Buy |
111,121
+9,887
| +10% | +$814K | 1.62% | 15 |
|
|
2025
Q2 | $8.01M | Buy |
101,234
+10,535
| +12% | +$837K | 1.47% | 17 |
|
|
2025
Q1 | $8.14M | Buy |
90,699
+15,452
| +21% | +$1.44M | 1.69% | 11 |
|
|
2024
Q4 | $7.49M | Buy |
75,247
+64,878
| +626% | +$6.69M | 1.52% | 12 |
|
|
2024
Q3 | $1.18M | Hold |
10,369
| – | – | 0.23% | 82 |
|
|
2024
Q2 | $1.28M | Sell |
10,369
-461
| -4% | -$59.4K | 0.28% | 81 |
|
|
2024
Q1 | $1.43M | Hold |
10,830
| – | – | 0.31% | 82 |
|
|
2023
Q4 | $1.18M | Buy |
10,830
+799
| +8% | +$82.9K | 0.28% | 84 |
|
|
2023
Q3 | $1.03M | Buy |
10,031
+161
| +2% | +$17.4K | 0.27% | 87 |
|
|
2023
Q2 | $1.14M | Sell |
9,870
-40
| -0.4% | -$4.54K | 0.29% | 84 |
|
|
2023
Q1 | $1.05M | Sell |
9,910
-25,139
| -72% | -$2.71M | 0.28% | 82 |
|
|
2022
Q4 | $3.92M | Sell |
35,049
-3,233
| -8% | -$330K | 1.06% | 44 |
|
|
2022
Q3 | $3.32M | Buy |
38,282
+538
| +1% | +$48K | 1% | 53 |
|
|
2022
Q2 | $3.49M | Sell |
37,744
-52,081
| -58% | -$4.62M | 1.02% | 46 |
|
|
2022
Q1 | $7.36M | Buy |
89,825
+8,597
| +11% | +$678K | 1.8% | 7 |
|
|
2021
Q4 | $6.22M | Buy |
81,228
+409
| +0.5% | +$32.6K | 1.72% | 14 |
|
|
2021
Q3 | $6.07M | Buy |
80,819
+8,704
| +12% | +$662K | 1.89% | 10 |
|
|
2021
Q2 | $5.61M | Buy |
72,115
+1,001
| +1% | +$74.5K | 1.81% | 14 |
|
|
2021
Q1 | $5.23M | Buy |
71,114
+7,810
| +12% | +$576K | 1.9% | 10 |
|
|
2020
Q4 | $4.94M | Buy |
63,304
+1,736
| +3% | +$133K | 2.02% | 8 |
|
|
2020
Q3 | $4.87M | Buy |
61,568
+7,073
| +13% | +$554K | 2.57% | 6 |
|
|
2020
Q2 | $4.02M | Sell |
54,495
-45
| -0.1% | -$3.39K | 2.28% | 7 |
|
|
2020
Q1 | $4M | Buy |
54,540
+18,489
| +51% | +$1.45M | 2.41% | 7 |
|
|
2019
Q4 | $3.13M | Buy |
36,051
+1,991
| +6% | +$164K | 1.68% | 14 |
|
|
2019
Q3 | $2.74M | Buy |
34,060
+33,836
| +15,105% | +$2.71M | 1.61% | 21 |
|
|
2019
Q2 | $18K | Buy |
224
+14
| +7% | +$1.07K | 0.01% | 147 |
|
|
2019
Q1 | $17K | Sell |
210
-419
| -67% | -$31.3K | 0.01% | 158 |
|
|
2018
Q4 | $46K | Sell |
629
-2,384
| -79% | -$168K | 0.03% | 126 |
|
|
2018
Q3 | $204K | Sell |
3,013
-33,326
| -92% | -$2.12M | 0.13% | 91 |
|
|
2018
Q2 | $2.1M | Buy |
36,339
+1,257
| +4% | +$70.9K | 1.48% | 16 |
|
|
2018
Q1 | $1.82M | Buy |
35,082
+8,175
| +30% | +$442K | 1.36% | 28 |
|
|
2017
Q4 | $1.45M | Buy |
+26,907
| New | +$1.49M | 1.12% | 44 |
|
Other funds holding MRK
VCM
VPM
Providence Capital Advisors's MRK Position: Q1 2026 in Review
Providence Capital Advisors reduced its Merck (MRK) stake by 3.8% in Q1 2026, selling an estimated $118K and leaving 26,099 shares worth $3.14M. The position accounts for 0.51% of the portfolio, ranked #72.
Providence Capital Advisors first reported a position in MRK in Q4 2017 and has held it in 34 quarters since. The position peaked at $9.33M in Q3 2025. 3,778 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Providence Capital Advisors held 26,099 shares of Merck worth $3.14M as of Q1 2026.
- Providence Capital Advisors sold 1,022 Merck shares in Q1 2026, an estimated $118K.
- Merck made up 0.51% of Providence Capital Advisors's portfolio in Q1 2026, its #72 holding.
- Providence Capital Advisors first reported a position in Merck in Q4 2017 and has held it in 34 quarters since.
- Providence Capital Advisors's Merck position peaked at $9.33M in Q3 2025.
- 3,778 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Providence Capital Advisors's 13F filing for Q1 2026, filed 14 May 2026.